<DOC>
	<DOCNO>NCT01890954</DOCNO>
	<brief_summary>The purpose study use closed-loop Control-to-Range ( CTR ) system adolescent type 1 diabetes outpatient setting , evaluate CTR system 's ability significantly improve blood glucose level insulin bolus omit 30 gram carbohydrate snack insulin bolus insufficient amount carbohydrate consume meal . The primary objective study use closed-loop Control-to-Range ( CTR ) system significantly reduce post-prandial blood glucose excursion adolescent type 1 diabetes omit and/or under-bolus insulin either snacks meal . Up 20 subject age ≥13 ≤18 year old test .</brief_summary>
	<brief_title>Optimizing Closed-Loop Control Type 1 Diabetes Mellitus Adolescents</brief_title>
	<detailed_description>The purpose study use closed-loop Control-to-Range ( CTR ) system adolescent type 1 diabetes outpatient setting , evaluate CTR system 's ability significantly improve blood glucose level insulin bolus omit 30 gram carbohydrate snack insulin bolus insufficient amount carbohydrate consume meal . The CTR system comprise two algorithmic layer : ( ) A Safety Supervision Module ( SSM ) contain predictive insulin request dampener ( brake ) ; ( ii ) Range Correction Module ( RCM ) , consist ( ) Hyperglycemia Mitigation System , ( b ) Insulin Board controller . Both module receive continuous glucose monitoring ( CGM ) historical insulin delivery data . The SSM monitor safety subject 's continuous subcutaneous insulin infusion pump ( CSII ) prevent hypoglycemia . The RCM responsible optimize blood glucose ( BG ) control mitigate postprandial hyperglycemic excursion mix increase basal rate , potentially , isolated insulin bolus . To run CTR , use wearable artificial pancreas platform , know DiAs ( Diabetes Assistant ) consist smart phone run CTR connect standard insulin delivery CGM device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . ≥13 ≤18 year old 2 . Clinical diagnosis type 1 diabetes mellitus least 2 year note follow : Criteria document hyperglycemia ( least 1 criterion must meet ) : Fasting glucose ≥126 mg/dL confirm Twohour Oral Glucose Tolerance Test ( OGTT ) ≥200 mg/dL confirm Hemoglobin A1c ( HbA1c ) ≥6.5 % documented history confirm Random glucose ≥200 mg/dL symptoms No data diagnosis available participant convince history hyperglycemia consistent diabetes Criteria require insulin diagnosis ( least 1 criterion must meet ) : Participant require insulin diagnosis continually thereafter Participant start insulin diagnosis upon investigator review likely need insulin ( significant hyperglycemia respond oral agent ) require insulin eventually use continually Participant start insulin diagnosis continue hyperglycemic , positive islet cell antibody consistent Latent Autoimmune Diabetes Adults ( LADA ) require insulin eventually use continually 3 . Use insulin pump treat his/her diabetes least 6 month 4 . Actively use carbohydrate ( CHO ) /insulin ratio insulin bolus adjustment order keep blood glucose predefined range 5 . Tanner stage II great base physician exam 6 . HbA1c &lt; 10.5 % measure DCA2000 equivalent device 7 . Not currently know pregnant , breast feeding , intend become pregnant ( female ) 8 . Demonstration proper mental status cognition study 9 . Willingness avoid consumption acetaminophencontaining product study visit involve DexCom use 10 . Selfreported behavior snack without insulin coverage bolus meal 11 . Willingness consume 30 gram snack without insulin coverage willingness bolus 75 % usual treatment 80 gram lunch admission 12 . Willingness remove home CGM admission subject typically wear CGM 13 . Medication stability precede two month take antihypertensive , thyroid , antidepressant lipid lower medication 14 . Reported history miss inaccurate bolus treatment meal time 1 . Diabetic ketoacidosis ( DKA ) within 6 month prior enrollment 2 . In adherence One Touch Ultra 2 User Guide , subject hematocrit level 30 % 55 % exclude . Severe hypoglycemia result seizure loss consciousness 12 month prior enrollment 3 . Pregnancy ; breast feeding , intention become pregnant 4 . Uncontrolled arterial hypertension ( base rest blood pressure &gt; 95 percentile list accord age height percentile Harriet Lane Handbook Pediatrics ) 5 . Conditions may increase risk hypoglycemia uncontrolled coronary artery disease previous year ( e.g . history myocardial infarction , acute coronary syndrome , therapeutic coronary intervention , coronary bypass stenting procedure , stable unstable angina , episode chest pain cardiac etiology document electrocardiogram ( EKG ) change , positive stress test catheterization coronary blockage &gt; 50 % ) , congestive heart failure , history cerebrovascular event , seizure disorder , syncope , adrenal insufficiency , neurologic disease atrial fibrillation 6 . History systemic deep tissue infection methicillinresistant staph aureus Candida albicans 7 . History arrythmia 8 . Use device may pose electromagnetic compatibility issue and/or radiofrequency interference DexCom CGM ( implantable cardioverterdefibrillator , electronic pacemaker , neurostimulator , intrathecal pump , cochlear implant ) 9 . Anticoagulant therapy aspirin 10 . Oral steroid 11 . Medical condition require use acetaminophencontaining medication withhold 24 hour CGM insertion end study admission . 12 . Psychiatric disorder would interfere study task ( e.g . inpatient psychiatric treatment within 6 month prior enrollment ) 13 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 14 . Known current recent alcohol drug abuse 15 . Medical condition would make operating CGM , DiAs cell phone , insulin pump difficult ( e.g . blindness , severe arthritis , immobility ) 16 . Any skin condition prevents sensor pump placement abdomen arm ( e.g . bad sunburn , preexist dermatitis , intertrigo , psoriasis , extensive scarring , cellulitis ) 17 . Impaired hepatic function measure alanine aminotransferase aspartate aminotransferase ≥ three time upper reference limit 18 . Impaired renal function measure creatinine &gt; 1.2 time upper limit normal 19 . Uncontrolled microvascular ( diabetic ) complication ( diabetic nonproliferative retinopathy ) , history laser coagulation , proliferative diabetic retinopathy , know diabetic nephropathy ( microalbuminuria normal creatinine ) neuropathy require treatment 20 . Active gastroparesis require current medical therapy 21 . Uncontrolled thyroid disease 22 . Known bleed diathesis dyscrasia 23 . Known allergy medical adhesive , component insulin pump insertion set continuous glucose monitor sensor 24 . Active enrollment another clinical trial 25 . Use antidiabetic agent continuous subcutaneous insulin infusion ( CSII ) include longacting insulin , intermediateacting insulin , metformin , sulfonylurea , meglitinides , thiazolidinediones , dipeptidyl peptidase 4 ( DPP4 ) inhibitor , glucagonlike peptide 1 agonist alphaglucosidase inhibitor 26 . Subjects basal rate less 0.01 units/hour RESTRICTIONS ON USE OF OTHER DRUGS OR TREATMENTS 1 . Use antidiabetic agent CSII include longacting insulin , intermediateacting insulin , metformin , sulfonylurea , meglitinides , thiazolidinediones , DPP4 , inhibitor , glucagonlike peptide 1 agonist , alphaglucosidase inhibitor . 2 . Acetaminophen restrict 24 hour insertion allow continuous glucose monitor use . 3 . Medications block symptom hypoglycemia , include limited beta blocker . 4 . Subjects amylin analog ask withhold medication outpatient admission .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type 1 Diabetes Mellitus ( T1DM )</keyword>
	<keyword>Closed Loop Control ( CLC )</keyword>
	<keyword>Diabetes Assistant ( DiAs )</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
</DOC>